Delcath Systems
DCTH
18.79
-0.45
-2.34%
Delcath Systems
US · DCTH
#3706 by market cap
18.79
-0.45
-2.34%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 13 in the most recent period (2026/Q3).
- Total institutional ownership rose 16.2 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 68.29% +16.22pp
- Institutions
- 164 +13
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund34.35%
Hedge Fund29.17%
Individual/Insider7.15%
Public Company3.91%
Government Pension Fund0.33%
Private Company0.22%
Insurance Company0.19%
VC/PE Fund0.12%
Other24.56%
Top holders as of 2026-10-13
Rosalind Advisors, Inc.
19.23% · 6.69M sh
BlackRock
11.49% · 4.00M sh
Daniel Kaufman
5.08% · 1.77M sh
Vanguard Capital Management, LLC
3.53% · 1.23M sh
Propel Bio Management, LLC
2.51% · 871.46K sh
Geode Capital Management, LLC
2.37% · 822.90K sh
State Street Global Advisors
2.18% · 759.94K sh
Algert Global LLC
1.67% · 580.71K sh
Millennium Management LLC
1.63% · 566.37K sh
Divisadero Street Capital Management, LP
1.44% · 499.80K sh
Morgan Stanley Investment Management Inc.
1.58% · 550.56K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 45 buys · 5 sells
| Name | Role | Stake |
|---|---|---|
| Rosalind Advisors, Inc. | -- | 19.23% |
| Gerard Michel | Chief Executive Officer | 0.98% |
| Vojislav Vukovic | Chief Medical Officer | 0.49% |
| David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | 0.25% |
| Sandra Pennell | Chief Financial Officer | 0.22% |
| Kevin Muir | Chief Commercial Officer | 0.07% |
| Gilad Aharon | Independent Director | 0.15% |
| John Sylvester | Independent Chairperson | 0.04% |
| Martha Rook | Chief Operating Officer | 0.02% |
| Elizabeth Czerepak | Independent Director | -- |
| Steven Salamon | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-11 | Bridget Martell | Director | Derivative Exercise and Sale | -22,500 | $7.85–22.26 |
| 2026-10-12 | Rosalind Advisors, Inc. | -- | Other Disposition | -23,875 | -- |
| 2026-10-12 | Rosalind Advisors, Inc. | -- | Derivative Exercise and Sale | -3,627 | -- |
| 2026-05-12 | Elizabeth Czerepak | Independent Director | Other Derivative Acquisition | +22,500 | $11.61 |
| 2026-05-12 | Steven Salamon | Independent Director | Other Derivative Acquisition | +22,500 | $11.61 |
| 2026-05-12 | John Sylvester | Independent Chairperson | Other Derivative Acquisition | +22,500 | $11.61 |
| 2026-05-12 | Gilad Aharon | Independent Director | Other Derivative Acquisition | +22,500 | $11.61 |
| 2026-05-12 | Bridget Martell | Director | Other Derivative Acquisition | +22,500 | $11.61 |
| 2026-03-05 | Sandra Pennell | Chief Financial Officer | Open Market Acquisition | +5,533 | $9.04 |
| 2026-03-01 | Gerard Michel | Chief Executive Officer | Open Market Acquisition | +11,200 | $8.96 |
| 2026-02-16 | Gerard Michel | Chief Executive Officer | Other Derivative Acquisition | +97,500 | -- |
| 2026-02-16 | Gerard Michel | Chief Executive Officer | Other Derivative Acquisition | +195,000 | $9.40 |
| 2026-02-16 | Vojislav Vukovic | Chief Medical Officer | Other Derivative Acquisition | +28,250 | -- |
| 2026-02-16 | Vojislav Vukovic | Chief Medical Officer | Other Derivative Acquisition | +56,500 | $9.40 |
| 2026-02-16 | Sandra Pennell | Chief Financial Officer | Other Derivative Acquisition | +28,250 | -- |
| 2026-02-16 | Sandra Pennell | Chief Financial Officer | Other Derivative Acquisition | +56,500 | $9.40 |
| 2026-02-16 | Martha Rook | Chief Operating Officer | Other Derivative Acquisition | +28,250 | -- |
| 2026-02-16 | Martha Rook | Chief Operating Officer | Other Derivative Acquisition | +56,500 | $9.40 |
| 2026-02-16 | David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | Other Derivative Acquisition | +28,250 | -- |
| 2026-02-16 | David Hoffman | General Counsel, Corporate Secretary & Chief Compliance Officer | Other Derivative Acquisition | +56,500 | $9.40 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Delcath Systems discussion 0 comments